標(biāo)題: Titlebook: Regulatory Aspects of Gene Therapy and Cell Therapy Products; A Global Perspective Maria Cristina Galli Book 2023Latest edition The Editor( [打印本頁] 作者: 審美家 時(shí)間: 2025-3-21 19:57
書目名稱Regulatory Aspects of Gene Therapy and Cell Therapy Products影響因子(影響力)
書目名稱Regulatory Aspects of Gene Therapy and Cell Therapy Products影響因子(影響力)學(xué)科排名
書目名稱Regulatory Aspects of Gene Therapy and Cell Therapy Products網(wǎng)絡(luò)公開度
書目名稱Regulatory Aspects of Gene Therapy and Cell Therapy Products網(wǎng)絡(luò)公開度學(xué)科排名
書目名稱Regulatory Aspects of Gene Therapy and Cell Therapy Products被引頻次
書目名稱Regulatory Aspects of Gene Therapy and Cell Therapy Products被引頻次學(xué)科排名
書目名稱Regulatory Aspects of Gene Therapy and Cell Therapy Products年度引用
書目名稱Regulatory Aspects of Gene Therapy and Cell Therapy Products年度引用學(xué)科排名
書目名稱Regulatory Aspects of Gene Therapy and Cell Therapy Products讀者反饋
書目名稱Regulatory Aspects of Gene Therapy and Cell Therapy Products讀者反饋學(xué)科排名
作者: inscribe 時(shí)間: 2025-3-21 23:30 作者: Ordeal 時(shí)間: 2025-3-22 03:16
Regulatory Oversight of Cell, Tissue, and Gene Therapy Products in Singapore,innovative CTGTP with a least burdensome regulatory framework while ensuring reasonable safeguards on the safety, quality, and efficacy of the products. This chapter describes the regulatory oversight of CTGTP in Singapore.作者: Indigence 時(shí)間: 2025-3-22 06:30
Regulatory Aspects of Cell and Gene Therapy Products: The Japanese Perspective,f a new scheme for obtaining conditional and time-limited approval for CGT products. Overall, research and development on CGT products, especially gene therapy products, is progressing. New legislative frameworks have been designed to promote the timely development of new technologies and safe and effective CGT products for Japanese patients.作者: 壓碎 時(shí)間: 2025-3-22 10:19
Regulatory Oversight of Cell and Gene Therapy Products in Malaysia,h-risk CGTP is similar to other biological products. This chapter describes the chronology of the CGTP framework, classification of CGTP, how CGTPs fit into the current registration pathways and registration procedure, dossier requirements, and what is the current status and future direction of CGTP in Malaysia.作者: 遵循的規(guī)范 時(shí)間: 2025-3-22 13:20
Regulatory Frameworks for Advanced Therapy Medicinal Products in Thailand,products are applied to ATMP in clinical trials and marketing authorization applications. At the same time, the specific guidelines for ATMPs are under development. This chapter provides an overview of the Thai FDA regulatory oversight of ATMPs, which covers investigational ATMPs, GMP certification, and marketing authorization.作者: addition 時(shí)間: 2025-3-22 19:40 作者: 賭博 時(shí)間: 2025-3-23 01:07
Book 2023Latest editionrica, Europe and Asia and by international bodies in the effort of international harmonization..This book represents an update of the first edition, as it covers regulatory novelties and accumulated experience in the regions already addressed. In addition, this new edition offers a wider internation作者: 缺陷 時(shí)間: 2025-3-23 05:10
United States Food and Drug Administration Regulation of Human Cells, Tissues, and Gene Therapies,g others, throughout the entire product lifecycle. This chapter provides an overview of the science- and data-driven approach to US FDA regulatory oversight of cell and gene?therapy (CGT) products to ensure their safety and efficacy.作者: Anhydrous 時(shí)間: 2025-3-23 07:46
Marketing Regulatory Oversight of Advanced Therapy Medicinal Products in Europe,sue-engineered products. Under this framework, ATMP are authorised by the centralised procedure, coordinated by the European Medicines Agency (EMA), whereas clinical trial authorisations remain at the remit of each National Competent Authority. The Committee for Advanced Therapies is responsible for作者: 認(rèn)為 時(shí)間: 2025-3-23 09:51 作者: 結(jié)合 時(shí)間: 2025-3-23 14:47
The Regulation of Cell Therapy and Gene Therapy Products in Switzerland,roducts, Swissmedic, is the lead Regulatory Authority and its ATMP Division is responsible for the regulation of these products at the level of clinical trials and marketing authorization. CGTPs are regulated similarly to medicinal products. The legal basis is set by the Therapeutic Product Act, the作者: 充滿人 時(shí)間: 2025-3-23 20:11 作者: Bernstein-test 時(shí)間: 2025-3-24 01:47
United States Food and Drug Administration Regulation of Human Cells, Tissues, and Gene Therapies,for these products to treat diverse, often rare, clinical indications is promising. The Office of Therapeutic Products (OTP) in the Center for Biologics Evaluation and Research (CBER) at the United States Food and Drug Administration (US FDA) is responsible for the regulation of these products, amon作者: Blatant 時(shí)間: 2025-3-24 04:00
Canadian Regulatory Framework and Regulatory Requirements for Cell and Gene Therapy Products,nt regulations. Cellular products that meet certain criteria, including minimal manipulation and homologous use, may be subjected to a standards-based approach under the Safety of Human Cells, Tissues and Organs for Transplantation Regulations. The manufacture and clinical testing of cell and gene t作者: Redundant 時(shí)間: 2025-3-24 07:30
Advanced Therapy Products in Brazil: Regulatory Aspects,ular therapy products, tissue engineering products, and gene therapy products, which due to their complexity involve innovation and risks, optimized regulatory channels for their development and life cycle monitoring. The scientific elements and the compliance with applicable regulatory aspects are 作者: 分期付款 時(shí)間: 2025-3-24 12:32
Regulation of Clinical Research for Cellular and Gene Therapy Products in India,utic products. The US-FDA refers to this category of products as Cellular and Gene Therapy Products (CGTPs), while the European Medicines Agency, Europe, refers to them as Advanced Therapy Medicinal Products (ATMPs). The research and development (R&D) and final commercialization of these products ha作者: 消滅 時(shí)間: 2025-3-24 18:16 作者: 托人看管 時(shí)間: 2025-3-24 19:31 作者: 許可 時(shí)間: 2025-3-25 01:29 作者: Bernstein-test 時(shí)間: 2025-3-25 03:54 作者: 增減字母法 時(shí)間: 2025-3-25 08:11 作者: 獨(dú)白 時(shí)間: 2025-3-25 15:38 作者: Condescending 時(shí)間: 2025-3-25 19:51
ough there were great differences in the mean monthly air temperatures between the sites, the mean monthly daytime carbon uptake was almost equal at both sites during the peak growing period. The carbon- uptake values at the same PAR level were greater before noon than after noon, especially at TOEF作者: 善變 時(shí)間: 2025-3-26 00:01 作者: Cognizance 時(shí)間: 2025-3-26 01:44 作者: BRUNT 時(shí)間: 2025-3-26 07:57 作者: 泰然自若 時(shí)間: 2025-3-26 10:32
Olga Kolaj-Robin,Marie-Thérèse Duffour a smaller, deciduous, oak-hornbeam- Fig. 1. The location of the Niepolomice Forest in Southern Poland VI Preface Tilio Carpinetum forest. This huge forested area (11,000 ha) owes its survival in one of the most densely populated parts of Europe to a long period of protection as a royal hunting grou作者: Ethics 時(shí)間: 2025-3-26 16:31 作者: 婚姻生活 時(shí)間: 2025-3-26 17:51 作者: 輕快走過 時(shí)間: 2025-3-26 21:33
Varsha Dalal,Hem Lata,Gitika Kharkwal,Geeta Jotwanich section of the book. Formal presentation sessions, combined with field trips to research sites, introduced the invitees to the primary and secondary successional ecosystems with which we were dealing. A major wildfire, only 24 km from the University campus, was contained the week prior to the con作者: Ardent 時(shí)間: 2025-3-27 04:28 作者: Lipohypertrophy 時(shí)間: 2025-3-27 09:06
Wan-Yu Chao,Yi-Ting Chang,Yueh-Tung Tsai,Mei-Chen Huang,Yi-Chu Lin,Min-Mei Wu,Jo-Feng Chi,Chien-Lianignated parts of the boreal zone, usually in northern regions, as “l(fā)ower priority” zones that receive little or no fire protection, since fires that occurred there were thought to have little or no significant detrimental impact on public safety and forest values. The realisation that total fire exc作者: 損壞 時(shí)間: 2025-3-27 10:28 作者: BLAND 時(shí)間: 2025-3-27 14:14
Judith Arcidiaconocent interest in the global C balance and the role of terrestrial ecosystems focuses on year-to-year variation and the record of the past decades (Sarmiento et al. 1992; Chapter 10, Houghton; Chapter 3, Townsend et al. ). Analyses of forest C budgets that do not rely on . assumptions of steady-state作者: 禁令 時(shí)間: 2025-3-27 19:09 作者: Nomadic 時(shí)間: 2025-3-28 01:22
The Regulation of Cell Therapy and Gene Therapy Products in Switzerland,onize requirements for CGTPs, the ATMP Division is in constant exchange of information with foreign Regulatory Authorities and part of working groups of ICH, IPRP, and Ph.Eur. As CGTPs are biologically and technically complex, a risk-based approach is applied on a case-by-case basis for the evaluati作者: dowagers-hump 時(shí)間: 2025-3-28 05:08 作者: 四指套 時(shí)間: 2025-3-28 08:23 作者: Exonerate 時(shí)間: 2025-3-28 14:19
Advanced Therapy Products in Brazil: Regulatory Aspects,es, use in emergency situations by risk controls and specific monitoring mechanisms, principally those related to rare diseases without other therapeutic alternatives. The opportune access to the advance therapy product with safety, efficacy, and quality involves innovative normative elements that i作者: Infect 時(shí)間: 2025-3-28 16:53
Regulation of Clinical Research for Cellular and Gene Therapy Products in India,led scientific manpower and infrastructure, is also contributing to development of these innovative therapeutic products. Keeping in line with the international counterparts, the Indian regulators and government agencies have developed regulations and guidelines for stakeholders. This chapter summar作者: 易發(fā)怒 時(shí)間: 2025-3-28 21:04 作者: acrobat 時(shí)間: 2025-3-29 00:57
Book 2023Latest editionical research to licensure and therapeutic use of these innovative products.??More specifically, each chapter offers insights into fundamental considerations that are essential for developers of Advanced Therapy Medicinal Products in the areas of product quality, pharmacology and toxicology, clinica作者: 背書 時(shí)間: 2025-3-29 05:32 作者: fallible 時(shí)間: 2025-3-29 07:27 作者: SOW 時(shí)間: 2025-3-29 12:39 作者: 排斥 時(shí)間: 2025-3-29 16:08
red ecosystem services. The target audience of this book is upper-level undergraduate and graduate students and professionals interested in forest health andentomology..978-3-031-11555-4978-3-031-11553-0作者: 異教徒 時(shí)間: 2025-3-29 19:59 作者: collateral 時(shí)間: 2025-3-30 03:47
Regulatory Aspects of Gene Therapy and Cell Therapy ProductsA Global Perspective作者: Permanent 時(shí)間: 2025-3-30 06:29 作者: 男生如果明白 時(shí)間: 2025-3-30 09:24
Martina Schuessler-Lenz,Carla Herberts,Ilona Reischl,Sol Ruiz,Patrick Celis,Claire Beuneu,Rune Kjekeing the eddy covariance method, in a Japanese cypress forest in the Kiryu Experimental Watershed (KEW) in central Japan. The net CO. exchange data during periods of low-friction velocity conditions and during periods of missing data were interpolated. The daily CO. uptake was observed throughout the作者: Comedienne 時(shí)間: 2025-3-30 14:12
Juan Estévez álamo,Marcos Timón,Isabel Sánchez Afán de Rivera,Beatriz Iriarte Torres,M. Antonia Serrdiurnal and seasonal variation, (2) simultaneous measurements of canopy-scale fluxes of heat and CO. and the normalized difference vegetation index (NDVI), (3) the stomatal conductance of sunlit and shaded leaves, (4) a stomatal conductance model, and (5) the effects of leaf age on stomatal conducta作者: 漂泊 時(shí)間: 2025-3-30 18:58
